Top Links

Articles Related to Survival

Adverse Drug Events and Predictors of One Year Survival among Adult Patients with Acute Myeloid Leukemia in a Kenyan Tertiary Health Facility

Treatment of acute myeloid leukemia is a challenge because of the adverse drug events associated with therapy and the heterogeneous nature of the subtypes. Research on improving overall survival of patients based on different regimens, reduction of adverse dug events, clinical characteristics and the type of acute myeloid leukemia is critical.
View complete article: PDF  |  Full-text

Oral Carcinoma in Young-Clinico-Pathological Profile and Survival Outcomes in a North Indian Population

To study the prevalence, clinico-pathological profile and survival outcome of oral squamous cell carcinoma in young patients (<40 years).
View complete article: PDF  |  Full-text

Long-Term Survival in Glioblastoma: Case Report

Glioblastoma is the most common and most deadly type of primary brain malignant tumors. despite applying the best trimodal treatment consisting of surgery chemoterapy and radiotherapy, there are few patients who survive decades after treatment.
View complete article: PDF  |  Full-text

Degree of Malignancy of T-Cell Acute Lymphocytic Leukemia Related to Autofluorescence in an EL4-Based Model

T cell acute lymphocytic leukemia (T-ALL) is an aggressive hematologic malignancy in terms of its pathology and populations. It is important to understand the phenomenon of autofluorescence in living cells because normal and cancer cells can be distinguished by this feature. However, the autofluorescence link to T-ALL is poorly understood.
View complete article: PDF  |  Full-text

The Development of the Prognostat Tool for Survival Prediction in Palliative Care Patients

Since a common question arises toward the end of life about prognosis and that clinicians vary widely in the accuracy of their survival predictions, it is important that advancements be developed, one of which is to design or improve prognostic tools. To test the reliability of the new Prognostat tool for survival. Prospective multi-site mixed methods study with data collection, survey, and focus groups. prediction in palliative care patients. Prognostat form completed during first assessment by a palliative physician or nurse on admission to a palliative care unit or first ward or home consult.
View complete article: PDF  |  Full-text

Prevention and Treatment of Esophageal Cancer in China: Achievements and Challenges-Prevention is the Key

Background: The study investigated esophageal cancer etiology and pathology, along with problems associated with surgical treatments. Keywords: Esophageal cancer; Mortality; Etiology; Pathology; Treatment; 5-year survivalIntroduction Methods: Data from the National Cancer Prevention and Control Office and the National Cancer Registry Center (2012) were assessed for information regarding malignant tumor incidence. These data were also used to conduct a mortality analysis and investigate death records pertaining to esophageal cancer patients. We extracted crude and age-specific mortality data and proportional mortality ratios as well as standard mortality data for Chinese and world populations. Esophageal cancer mortality was compared with death statistical data and literature related to esophageal cancer was collected from the Chinese Biomedical Literature Database and the Chinese Journal Network.
View complete article: PDF  |  Full-text

Evaluation of Prognostic Factors and Survival Results in Pediatric Hodgkin’s Lymphoma-single center experience from Eastern Black Sea Region of Turkey

View complete article: PDF  |  Full-text

Liquid Biopsy in Advanced Gastric Malignancy and Molecular Targeted Therapy; a Case Report and Update Pertaining Anti HER2-Neu Therapy

Human epidermal growth factor receptor 2 (HER2) is responsible for the pathogenesis and poor outcomes of several types of cancers, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs on the other hand, such as trastuzumab, prolong overall survival and progression-free survival in HER2-positive gastric cancer. The purpose of the case report is to evaluate the impact of delivering trastuzumab in advanced gastric cancer with concomitant HER2 mutation and amplification.
View complete article: PDF  |  Full-text

Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis

We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.
View complete article: PDF  |  Full-text

Effect of Neoadjuvant Chemoradiotherapy on Pathologic Stage and Survival in Patients with Locally Advanced Esophageal Cancer

The treatment of resectable stages of esophageal cancer often involves pre-operative concurrent chemoradiotherapy. This study aims to evaluate the effect of cisplatin/5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer.
View complete article: PDF  |  Full-text

Gastroesophageal Cancer: Prognostic Factors and Treatment Results

The study presents the remote results of surgical treatment of 329 patients with cancer of gastroesophageal localization. Three 3-year survival rate is 37.1%, the 5-year survival rate is 26.2%. Prognosis after the surgery depends primarily on the extent of the tumour spread.
View complete article: PDF  |  Full-text

Clinical Evaluation of 762 Single-Tooth, Locking-Taper Implants: A Prospective Study with 1- to 12-Years of Follow-Up

The aim of this study was to evaluate the survival rate, complications and marginal bone loss of single-tooth lockingtaper implants.
View complete article: PDF  |  Full-text


Editorial Board Members Related to Survival

HONGYU LI

Associate Professor
Department of Gastroenterology
Shenyang Northern Hospital
China

Jonathan R. Keller

Principal Investigator
Hematopoiesis and Stem Cell Biology Section
Center for Cancer Research
National Cancer Institute
United States

Asma Amleh

Assistant Professor
Department of Biology
American University in Cairo
Egypt

Naiji Lu

Assistant Professor
Department of Biostatistics and Computational Biology
University of Rochester
United States

PAULA M. CHILTON

Assistant Professor
Department of Microbiology & Immunology
University of Louisville
United States

Tao Liu

Children's Cancer Institute
University of New South Wales
Australia

Shi J. Liu

Professor
Department of Pharmaceutical Sciences
University of Arkansas for Medical Sciences
United States

Hongbin Fang

Associate Professor
Department of Biostatistics, Bioinformatics & Biomathematics
Georgetown University
United States
Submit Manuscript


Open Access Journals

View All Journals